Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective.
Marjolein de Bruin-WellerJoseph Frank MerolaH Chih-Ho HongEsther Serra BaldrichKarel EttlerDebra SierkaDimittri DelevryZhen ChenAna Beatris RossiPublished in: Dermatology and therapy (2021)
Adult patients with AD perceived that dupilumab with/without concomitant TCS was highly efficacious and improved overall disease status and well-being as early as week 2 and throughout treatment periods up to 1 year. Video Abstract (MP4 90521 kb).